Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria. Read More
It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed and refractory multiple myeloma. A bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, Lynozyfic was cleared under the accelerated approval pathway, with continued approval contingent upon a confirmatory trial.
In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative steps Congress may take in response to allegations that Pfizer slow-walked its COVID-19 vaccine development in 2020 so the trial results wouldn’t have to be disclosed until after the presidential election. Read More
Puretech Health plc’s rollout May 20 of more phase IIb data with deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF) perked optimism for that compound – a deuterated form of p38 MAP kinase inhibitor pirfenidone – as well as others in the busy therapeutic space. Read More
Lizards, zebrafish, salamanders and tritons can regrow a tail, a fin, or even an entire limb after amputation. Cut a planarian into pieces, and you will end up with a bunch of them. Researchers at the National Institute of Biological Sciences in Beijing have discovered a genetic switch linked to vitamin A. After activating this pathway, they managed to regenerate the ear pinna of a mouse, an animal that previously lacked this ability. Read More
The BioWorld Cancer Index reversed its early year losses, rebounding from a 4.74% decline at the end of the first quarter (Q1) to finish Q2 up 12.78%. The Dow Jones Industrial Average followed a similar pattern, dropping to -4.41% by the end of April before recovering to a 3.64% gain by Q2’s end. Meanwhile, the Nasdaq Biotechnology Index, down 5.37% at the end of May, narrowed its losses to close June down just 1.92%. Read More
BioWorld's newly launched index insights page provides an in-depth look at sector performance across six major indices. Get access to the latest index charts, top-performing companies and recent stories highlighting trends in the biopharma, drug developers, cancer, infectious disease and neurological sectors. Read More
New hires and promotions in the biopharma industry, including: Avacta, Bayer, Bluebird, Genmab, Jade, Mallia, Marea, Outlook, Preveceutical, T-knife, Taxis, Zura. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Arcturus, Atai, Beckley, Cytodyn, I-Mab, Mineralys, Sensorion, Verastem. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abeona, Alvotech, Advanz, Bergenbio, Beacon, Bioeq, Biomarin, Bio Usawa, Concentra, Ho’ola, IGM, Inozyme, Merck, Oncoinvent, Oncternal, Protagonist, Torii, Verrica. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Camurus, Clene, Hemispherian, Jazz, Mesoblast, Vertex. Read More
